MDGL
MDGL
View Detailed Chart
437.850USD
+0.680+0.16%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
9.73BMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.16%
5 Days
+5.59%
1 Month
+51.05%
6 Months
+28.30%
Year to Date
+41.90%
1 Year
+77.17%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-29Key Insights
The company's fundamentals are relatively very weak.Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a very weak stock market performance, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
16
analysts
Buy
Current Rating
415.786
Target Price
+25.53%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 57.74.
Undervalued
The company’s latest PE is -34.62, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.67M shares, decreasing 6.19% quarter-over-quarter.
Held by John Paulson
Star Investor John Paulson holds 2.09M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.06.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Ticker SymbolMDGL
CompanyMadrigal Pharmaceuticals Inc
CEOMr. Bill Sibold
Websitehttps://www.madrigalpharma.com/
Related Instruments
+1.15%
+2.29%
+1.03%
+2.72%
+0.84%
-1.89%
-2.95%
+1.65%
+0.54%
+2.99%
+0.19%
-1.27%
+0.87%
+3.28%
+1.00%
+0.55%
0.00%
+0.17%
-0.93%
-8.05%
